Tezruly™ (terazosin) oral solution
Approval Date: Jul 2024
Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate
Entresto® (sacubitril and valsartan) tablets
Approval Date: May 2024
Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure
Winrevair™ (sotatercept-csrk) injections
Approval Date: Mar 2024
A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events
Opsynvi® (macitentan and tadalafil) tablets
Approval Date: Mar 2024
Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both
Tryvio™ (aprocitentan) tablets
Approval Date: Mar 2024
Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure
Katerzia® (amlodipine benzoate) oral suspension
Approval Date: Jun 2023
For the treatment of hypertension and coronary artery disease
Inpefa™ (sotagliflozin) tablets
Approval Date: May 2023
Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes
Byvalson™ (nebivolol and valsartan) tablets
Approval Date: Sep 2022
Indicated for the treatment of hypertension, to lower blood pressure
Edarbi® (azilsartan medoxomil) tablets
Approval Date: Jul 2022
Indicated for the treatment of hypertension to lower blood pressure
Norliqva® (amlodipine) oral solution
Approval Date: Feb 2022
A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.
